Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

FIVE at FIVE: De Pfeffel kerfuffle; Musk in handbrake turn; Countryside Partnerships under siege; AstraZeneca finds market hard to please

Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news.

1. Voting kerfuffle for Alexander Boris de Pfeffel Johnson

The pound was the best performing major currency after news emerged that a vote of no-confidence in prime minister Boris Johnson would take place in Westminster this evening.

Read more

2. Elon Musk in handbrake turn

Elon Musk made a U-turn on his plan to cut 10% of the electric car maker's workforce. He’s going to cut 20% … just kidding. "Total headcount will increase, but salaried should be fairly flat," Musk tweeted. It’s almost like we can’t believe a single word he says.

Read more

3. Why are two US hedge funds so interested in an underperforming British housebuilder?

Possible answers: it’s cheap; it has good cash flow; it has lots of assets to flog off; all of the aforementioned.

Read more

4. FTSE not fazed by the prospect of political upheaval

At the close, the UK blue-chip index was 75.27 points, or 1% higher at 7,608.22, below the session peak of 7,646.66 but well above the day's early low of 7,532.84. Meanwhile Foreign exchange markets seemed to like the prospect of Boris Johnson getting to spend more time with his families, and equity investors did not seem too frightened by it either

Read more

5. AstraZeneca finds the market hard to please

The pharma giant reportedly received a standing ovation when it announced the results of its DESTINY-Breast04 clinical trials on metastatic breast cancer treatment at the seminal ASCO cancer conference on Sunday, but even so, its shares were among the few blue-chips to lose ground today.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK